ライフサイエンスコーパス: 18F

1 18F-AV-1451 binding to the basal ganglia was strong in a

2 18F-CP18 may be useful for detection of anthracycline-in

3 18F-FDG PET is an early predictor of survival in patient

4 18F-FDG PET/CT scans of gluteal and quadriceps muscle ar

5 18F-FDG uptake was particularly high in subjects with pe

6 18F-FDG-PET-CT scans revealed almost complete inhibition

7 18F-Fluoride positron emission tomography (PET) and comp

8 18F-fluorodeoxyglucose positron emission tomography was

9 18F-flutemetamol PET was performed in 321 subjects.

10 18F-flutemetamol retention, but not CSF Abeta42, correla

11 18F-NaF is a promising new approach for the assessment o

12 18F-NaF uptake displayed a progressive rise with valve s

13 18F-NaF uptake identifies active tissue calcification an

14 18F-PFH was synthesized by reacting N-succinimidyl-4-18F

15 18F-Sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose

16 [18F]-10b and [18F]-10a showed comparable striatum-to- ce

17 [18F]-FDG PET-CT scans revealed a relative increase in gl

18 [18F]F-AraG may be useful for imaging activated T cells i

19 [18F]F-AraG PET imaging of a murine aGVHD model enabled v

20 [18F]fluoro-2-deoxy-D-glucose uptake rate was computed fo

21 d 6 thoracic (thoracic aortic), who had >/=1 18F-FDG positron emission tomography/computed tomography

22 PET/CT interpreters analyzing a subset of 13 18F-fluoride PET/CT scans.

23 agreement of +/-0.21 (18F-NaF) and +/-0.13 (18F-FDG) for maximum tissue-to-background ratios.

24 : Imaging with fluorine 18-labeled AV-1451 ([18F]AV-1451) (formerly known as [18F]T807), [11C]PiB PET

25 gs measured by fluorine 18-labeled AV-1451 ([18F]AV-1451) positron emission tomographic (PET) imaging

26 mean age+/-SD, 65.7+/-14.2 y) underwent 158 18F-fluoride PET/CT scans for evaluation of skeletal met

27 d >80% reduction in myocardial uptake of 16-[18F]fluoro-4-thiahexadecanoic acid (2) and 3, indicating

28 ts (18F-NaF: 2.87+/-0.82 versus 1.55+/-0.17; 18F-FDG: 1.58+/-0.21 versus 1.30+/-0.13; both P<0.001).

29 individuals underwent fludeoxyglucose F 18 ([18F]-FDG) positron emission tomographic scanning for ass

30 e symptoms who underwent flutemetamol F 18 ([18F]flumetamol) positron emission tomography amyloid ima

31 2014) who had undergone flutemetamol F 18 ([18F]flutemetamol)-labeled PET.

32 icipants were studied with florbetapir F 18 [18F] PET.

33 18-[18F]Fluoro-4-thia-(9Z)-octadec-9-enoic acid (3) showed e

34 18-[18F]Fluoro-6-thiaoctadecanoic acid (5) showed moderate m

35 In contrast, 18-[18F]fluoro-4-thiaoctadecanoic acid (4) showed dramatical

36 man thymidine kinase 2 (TK2) and 2'-deoxy-2'-18F-5-methyl-1-beta-L-arabinofuranosyluracil (L-18F-FMAU

37 w that a novel PET radiotracer, 2'-deoxy-2'-[18F]fluoro-9-beta-D-arabinofuranosylguanine ([18F]F-AraG

38 al present their experience with 2-deoxy-2-[18F] fluoroglucose/positron emission tomography (FDG/PET

39 nd biodistribution analysis using 2-deoxy-2-[18F]fluoro-D-glucose that reprogramming of intestinal gl

40 n tomography scanning and the radiotracer 2-[18F]fluoro-3-(2(S)azetidinylmethoxy) pyridine (also know

41 Although 2[18F]fluoro-2-deoxy-d-glucose (FDG) uptake during positro

42 l biases and limits of agreement of +/-0.21 (18F-NaF) and +/-0.13 (18F-FDG) for maximum tissue-to-bac

43 he radiolabeled CB1 antagonist (3R,5R)-5-(3-(18F-fluoromethoxy)phenyl)-3-(((R)-1-phenylethyl)amino)-1

44 al biodistribution and kinetics of (S)-4-(3-[18F]fluoropropyl)-l-glutamic acid ((18)F FSPG) in health

45 of illness) and 48 older (age 30 years; 30M/18F) patients were age-matched to younger and older heal

46 lus two 18F-labeled PET reporters FHBG [9-(4-18F-fluoro-3-[hydroxymethyl] butyl) guanine] and FLT (18

47 was synthesized by reacting N-succinimidyl-4-18F-fluorobenzoate (18F-SFB) with glycine at 90 degrees

48 Sixty-five younger (age <30 years; 47M/18F) patients with psychosis (all experiencing a first e

49 We used 6-[18F]-dopamine (18F-DA) to track myocardial uptake and re

50 resonance imaging and baseline PETs using 6-[18F]fluorodopa (FD), [11C]dihydrotetrabenazine (DTBZ), a

51 Abnormal 18F-flutemetamol retention levels correlate with disease

52 ased vesicular 18F-DA uptake and accelerated 18F-DA loss, compared with MSA and control subjects.

53 benzyl)-N-(4-phenoxypyridin-3-yl)acetamide ([18F]FEPPA).

54 A metabolite 18F-dihydroxyphenylacetic acid (18F-DOPAC).

55 underwent fluorodihydroxyphenyl-l-alanine ([18F]-DOPA) positron emission tomography to examine dopam

56 nsufflated with CO2 to displace the lung, an 18F sheath was delivered to the left atrium, and the lef

57 An [18F]-AV-1451 SUVR cutoff value of 1.19 (sensitivity, 100

58 nstance, the radiolabeled glucose analogue, [18F]fluorodeoxyglucose (FDG), is routinely used in posit

59 Using PET with 11C-acetate, 18FDG, and 18F-fluoro-thiaheptadecanoic acid (18FTHA), a fatty acid

60 en Abeta classification with CSF Abeta42 and 18F-flutemetamol positron emission tomography was very h

61 er, namely 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

62 on and computed tomography using 18F-NaF and 18F-FDG radiotracers.

63 We compared 18F-NaF and 18F-FDG uptake with histological characterization of the

64 their coronary calcium score and 18F-NaF and 18F-FDG uptake.

65 stenosis) were administered both 18F-NaF and 18F-FDG.

66 18F-Sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) are promising novel bio

67 uptake of 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) as markers of active pl

68 ssessed by 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) uptake with the use of

69 Alzheimer's disease slices with 11C-PBB3 and 18F-AV-1451 were noted.

70 ith differential affinities for 11C-PBB3 and 18F-AV-1451, and higher availability of binding sites on

71 nd measured their coronary calcium score and 18F-NaF and 18F-FDG uptake.

72 x computed by finite element simulations and 18F-FDG uptake were evaluated in a total of 68 examinati

73 stigated with finite element simulations and 18F-fluoro-deoxy-glucose (18F-FDG) positron emission tom

74 [18F]-10b and [18F]-10a showed comparable striatum-to- cerebellum ratio

75 lation of [18F]fluoropropyl ([18F]-10b) and [18F]fluoroethyl ([18F]-10a) derivatives of 8 in the brai

76 kin lesions confirmed the same disease, and [18F]fluorodeoxyglucose-positron emission tomography demo

77 deoxyglucose ([18F]-FDG) for glycolysis and [18F]-2-fluoro-D-(arabinofuranosyl)cytosine ([18F]-FAC) f

78 ology and behavioral imaging with muPET and [18F]fluorodeoxyglucose (FDG) to generate whole-brain met

79 8F]fluoro-9-beta-D-arabinofuranosylguanine ([18F]F-AraG), targeted toward two salvage kinase pathways

80 Arterial 18F-NaF uptake was quantified at the level of the ascend

81 demonstrated that quantification of arterial 18F-NaF uptake is affected by blood activity, injected d

82 ted dose affected quantification of arterial 18F-NaF uptake, whereas renal function and circulating t

83 hnical factors on quantification of arterial 18F-NaF uptake.

84 /CT system affect quantification of arterial 18F-NaF uptake.

85 actors can affect quantification of arterial 18F-NaF uptake.

86 d to generate accurate estimates of arterial 18F-NaF uptake.

87 The ratio of myocardial 18F-DA to arterial 18F-DOPAC provided an index of vesicular uptake.

88 as flortaucipir (18F-AV-1451, also known as 18F-T807) have made it possible to investigate the seque

89 d AV-1451 ([18F]AV-1451) (formerly known as [18F]T807), [11C]PiB PET, magnetic resonance imaging (MRI

90 Baseline 18F-NaF uptake correlated closely with the change in cal

91 There was no significant correlation between 18F-FDG uptake and CD68 staining (r=-0.43; P=0.22).

92 dependent regressions were performed between 18F-AV-1451 binding and each cognitive domain, and we us

93 As a promising striatal imaging biomarker, [18F]MNI-659 is potentially capable of assessing the exte

94 vere aortic stenosis) were administered both 18F-NaF and 18F-FDG.

95 ng an association between cognition and both 18F-AV-1451 uptake and grey matter volume.

96 mmation in the aortic valve were assessed by 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose

97 lthy subjects were prospectively examined by 18F-NaF PET/CT imaging.

98 of cortical or subcortical hypometabolism by 18F-FDG PET is an unfavorable predictor.

99 We report two cases of SOS investigated by 18F-fluorodeoxyglucose positron emission tomography/comp

100 t levels of brain Abeta fibrils (measured by 18F-flutemetamol PET) are independently associated with

101 ng to diagnostic classifications provided by 18F-FDG PET at baseline and clinical diagnoses after a m

102 ethylation status, and metabolic response by 18F-fluorodeoxyglucose positron-emission tomography.

103 Risk stratification by 18F-FDG PET appears to be at least as predictive as the

104 best-fitting model to assess SMGU studied by 18F-FDG.

105 on brain glucose metabolism, as measured by [18F] deoxy-D-glucose brain positron emission tomography.

106 und effect on Patlak kinetics and calculated 18F-FDG uptake.

107 a caspase-3 substrate and evaluated cardiac 18F-CP18 uptake in a mouse model of anthracycline cardio

108 hout known cardiac disease underwent cardiac 18F-FDG-PET for assessment of arterial wall inflammation

109 We compared 18F-NaF and 18F-FDG uptake with histological characteriz

110 Patients with increased coronary 18F-NaF activity (n = 40) had higher rates of prior card

111 Quantification of coronary 18F-FDG uptake was hampered by myocardial activity and w

112 Inter-observer repeatability of coronary 18F-NaF uptake measurements (maximum tissue/background r

113 es are now needed to assess whether coronary 18F-NaF uptake represents a novel marker of plaque vulne

114 (95% CI, 11-24 years) for the mean cortical 18F-florbetapir standard uptake value ratio, age 15 year

115 Results: In patients with DLB, cortical [18F]AV-1451 uptake was highly variable and greater than

116 Elevated cortical [18F]AV-1451 binding was observed in 4 of 17 patients wit

117 den with 18F-labeled sodium fluoride PET/CT (18F-fluoride PET/CT) and evaluate the reproducibility of

118 18F]-2-fluoro-D-(arabinofuranosyl)cytosine ([18F]-FAC) for deoxycytidine salvage.

119 linical assessments, genetic determination, [18F]MNI-659 PET imaging, and brain magnetic resonance im

120 The 2-dimensional and 3-dimensional 18F-DTBZ PET images demonstrated that the reduction of v

121 lative to patients with Alzheimer's disease, 18F-AV-1451 binding was elevated in the midbrain (t = 2.

122 We used 6-[18F]-dopamine (18F-DA) to track myocardial uptake and retention of cate

123 e oximetry were measured in patients during [18F]FMISO and 15O PET imaging.

124 healthy male volunteers underwent 2 dynamic 18F-FDG PET/CT scans with an interval of 24 h.

125 nsulin treatment, reflecting the rapid early 18F-FDG uptake.

126 e of Abeta+ was associated with an elevated [18F]-AV-1451 SUVR in AD cortical signature regions (Abet

127 An elevated [18F]-AV-1451 SUVR was associated with volumetric loss in

128 Melanin targeted N-(2-(diethylamino)ethyl)-18F-5-fluoropicolinamide was used as a PET reporter prob

129 We have synthesized and evaluated 18F-labeled thia fatty acid analogues as metabolically t

130 in line with moderate 11C-PBB3 versus faint 18F-AV-1451 autoradiographic labelling of these tissues.

131 otracers in prostate cancer, namely 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

132 ion tomography tracers such as flortaucipir (18F-AV-1451, also known as 18F-T807) have made it possib

133 o-3-[hydroxymethyl] butyl) guanine] and FLT (18F-3'-deoxy-3-'fluorothymidine), respectively.

134 Sodium 18F-fluoride (18F-NaF) PET/CT imaging is a promising imaging technique

135 18F-Sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) are promis

136 nary arterial uptake of 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) as markers

137 valve were assessed by 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) uptake wit

138 eacting N-succinimidyl-4-18F-fluorobenzoate (18F-SFB) with glycine at 90 degrees C (pH 8) for 20 min.

139 uoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) are promising novel biomarkers of disease activ

140 uoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) as markers of active plaque calcification and i

141 uoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) uptake with the use of positron emission tomogr

142 bolic pathways: [18F]-2-fluorodeoxyglucose ([18F]-FDG) for glycolysis and [18F]-2-fluoro-D-(arabinofu

143 oropropyl ([18F]-10b) and [18F]fluoroethyl ([18F]-10a) derivatives of 8 in the brain.

144 Fluorine 18-labeled fluoromisonidazole ([18F]FMISO), a PET tracer that undergoes irreversible sel

145 mediated accumulation of [18F]fluoropropyl ([18F]-10b) and [18F]fluoroethyl ([18F]-10a) derivatives o

146 1), with a more modest increase observed for 18F-FDG (r(2)=0.218, P<0.001).

147 and advanced stages of PD were recruited for 18F-DTBZ PET scans from the Movement Disorders Clinic in

148 with disease severity and are strongest for 18F-NaF.

149 Regional uptakes for 18F-DTBZ PET of different disease stages were measured.

150 -CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practi

151 Furthermore, [18F]MNI-659 may identify early changes in medium spiny n

152 nt simulations and 18F-fluoro-deoxy-glucose (18F-FDG) positron emission tomography.

153 plored highly associated patterns of greater 18F-AV-1451 binding and increased annualized change in c

154 us brain regions was associated with greater 18F-AV-1451 PET retention most prominently in the inferi

155 For DLB and PD-impaired patients, greater [18F]AV-1451 uptake in the inferior temporal gyrus and pr

156 ghest correlations were in regions with high 18F-flutemetamol retention (eg, posterior cingulum and p

157 An inverse association between hippocampal [18F]-AV-1451 SUVR and volume was seen in Abeta+ particip

158 uantification software application to hybrid 18F-fluorodeoxyglucose positron emission tomography (PET

159 We found that: (i) 18F-AV-1451 positron emission tomography retention was d

160 t scans, 19 post-treatment scans); and (iii) 18F-fallypride imaging of an antipsychotic free Alzheime

161 sorders, and had completed amyloid imaging ([18F]-florbetapir) at baseline and cognitive assessments

162 A similar increase in 18F-CP18 uptake was observed by microPET (0.41+/-0.04 ve

163 Increased 18F-FDG positron emission tomographic uptake in aortic a

164 alsy showed, relative to controls, increased 18F-AV-1451 uptake in the putamen, pallidum, thalamus, m

165 8F-NaF uptake (>1.97), and 35% had increased 18F-FDG uptake (>1.63).

166 ents with aortic stenosis, 91% had increased 18F-NaF uptake (>1.97), and 35% had increased 18F-FDG up

167 strated >/=1 aneurysm wall area of increased 18F-FDG uptake.

168 ance in each domain was related to increased 18F-AV-1451 binding in specific brain regions conforming

169 There was increased 18F-AV-1451 binding in multiple regions in living patien

170 icin treatment was associated with increased 18F-CP18 uptake in %ID/g by gamma counting from 0.36+/-0

171 l events occurred in patients with increased 18F-FDG uptake on their last examination than in those w

172 suggested that the threshold for increased [18F]FMISO trapping is probably 15 mm Hg or lower.

173 Foci of increased [18F]AV-1451 binding in the inferior temporal gyrus and p

174 e of these categories based on their initial 18F-DA uptake.

175 e emerged on the prognostic role of interim [18F]-fluoro-2-deoxy-D-glucose positron emission tomograp

176 -5-methyl-1-beta-L-arabinofuranosyluracil (L-18F-FMAU) as the PRP.

177 We identified L-18F-FMAU as a candidate PRP and determined its biodistri

178 e findings suggest that the TK2-N93D/L109F/L-18F-FMAU PRG-PRP system warrants further evaluation in p

179 93D/L109F) that efficiently phosphorylates L-18F-FMAU.

180 One hour later, 18F-FDG was injected, followed by a 3-h dynamic PET scan

181 coronary arteries by calculating the maximum 18F-NaF activity (NaFmax), the maximum/mean target-to-ba

182 on was prospectively determined by measuring 18F-flourodeoxyglucose uptake (using baseline positron-e

183 erial plasma levels of the 18F-DA metabolite 18F-dihydroxyphenylacetic acid (18F-DOPAC).

184 The ratio of myocardial 18F-DA to arterial 18F-DOPAC provided an index of vesicu

185 died radiotracers in prostate cancer, namely 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

186 ty and specificity of positive and negative [18F] florbetapir PET categorization, which was estimated

187 Concurrently, the fate of intra-neuronal 18F-DA was followed by assessment of arterial plasma lev

188 were not associated with Abeta isoforms nor 18F-flutemetamol uptake.

189 resonance imaging-based spatially normalized 18F-DTBZ images for each participant.

190 The observed [18F]-AV-1451 SUVR volumetric association was modified by

191 ologic staining confirmed that the change of 18F-FPPRGD2 uptake correlated with the variation of inte

192 h direct and grey matter-mediated effects of 18F-AV-1451 uptake on cognitive performance.

193 uromelanin is an insufficient explanation of 18F-AV-1451 positron emission tomography data in vivo, a

194 were acquired simultaneously on injection of 18F-PBR06 (70-100 MBq/0.2 mL).

195 cted from a rat at 40 min after injection of 18F-PFH indicated that it was excreted intact, with no m

196 al rats at 10 min and 1 h after injection of 18F-PFH.

197 d ECG-gated PET-CT permitted localization of 18F-fluoride uptake to individual valve leaflets.

198 ponding to the cortical distribution maps of 18F-T807 and 11C-PiB.

199 A composite measure of 18F-flutemetamol uptake was not associated with WML, and

200 Cross-sectional measures of 18F-florbetapir positron emission tomography, 18F-fludeo

201 e after intravenous injection of 250 muCi of 18F-CP18, 24 hours post-doxorubicin treatment was quanti

202 Overall, we confirm the potential of 18F-AV-1451 as a heuristic biomarker, but caution is ind

203 These data suggest the potential of 18F-PBR06 to elucidate the role of TSPO in oncology, as

204 inding may contribute to disease profiles of 18F-AV-1451 positron emission tomography, especially in

205 What is the sensitivity and specificity of 18F-fludeoxyglucose-positron emission tomography/compute

206 onstrate relationships between structures of 18F-labeled thia fatty acid and uptake and their utility

207 we investigated coronary arterial uptake of 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose

208 ecipient bone marrow, while accumulation of [18F]-L-FMAU in hdCK3mut-expressing T cells permitted det

209 observed the A2AR-mediated accumulation of [18F]fluoropropyl ([18F]-10b) and [18F]fluoroethyl ([18F]

210 of [18F]AV-1451 binding, the association of [18F]AV-1451 binding with [11C]PiB binding, and the assoc

211 th [11C]PiB binding, and the association of [18F]AV-1451 binding with cognitive impairment.

212 iation of diagnostic groups on the basis of [18F]AV-1451 binding, the association of [18F]AV-1451 bin

213 maintained uptake and saturable binding of [18F]GV1-57 in primate nasal epithelium, supporting its t

214 We demonstrate our method on the GWAS of [18F]FDG-PET measures in the amygdala region using the im

215 ls were studied with dynamic PET imaging of [18F]fluoro-2-deoxy-D-glucose at two occasions with 24-ho

216 s strongly correlated with the magnitude of [18F]AV-1451 binding (3 patients with amnesic Alzheimer d

217 Standardized uptake value ratio (SUVR) of [18F]-AV-1451 in the hippocampus and a priori-defined AD

218 With combined ART, uptake of [18F]-FDG in the axillary lymph nodes, as measured by TBR

219 er, when stratifying for cortical uptake of [18F]flutemetamol in cohort C, APOE epsilon4 genotype did

220 in cases with or without cortical uptake of [18F]flutemetamol.

221 Use of [18F]-AV-1451 has a potential for staging of the preclini

222 variables, atrophy on MRI, hypometabolism on 18F-fluorodeoxyglucose positron emission tomography (FDG

223 in aortic target-background ratio (TBR) on [18F]-FDG-PET with combined ART in the HIV-infected group

224 Optimized 18F-fluoride PET-CT allows reproducible localization of

225 gnal intensity/contrast enhancement, and/or [18F]-fluorodeoxyglucose positron emission tomography [PE

226 robes for two different metabolic pathways: [18F]-2-fluorodeoxyglucose ([18F]-FDG) for glycolysis and

227 In PD, 18F-DTBZ PET is a potential imaging biomarker for measur

228 (n = 20, 65-79 years); (ii) pharmacokinetic, 18F-fallypride D2/3 receptor imaging and clinical outcom

229 between age and the mean cortical to pontine 18F-florbetapir standard uptake value ratios, precuneus

230 within a mean of 1.6 years, and a positive [18F] florbetapir baseline scan was associated with a 6.9

231 MTV and TLG was calculated from preoperative 18F-FDG PET/CT scans and analyzed as marker of biochemic

232 w prognostic factor measured on pretreatment 18F-fluorodeoxyglucose (18FDG)-positron emission tomogra

233 a follow-up of up to 5.9 y after prospective 18F-FDG PET imaging.

234 Quantitatively, 18F-FDG positron emission tomographic uptake correlated

235 We assessed the radiotracer 18F-AV-1451 with positron emission tomography imaging to

236 Using cerebellar gray reference, 18F-T807 data were expressed as standardized uptake valu

237 ke was not associated with WML, and regional 18F-flutemetamol uptake only with temporal WML.

238 ents with aortic stenosis underwent repeated 18F-fluoride PET-CT.

239 a completely negative scan or with residual [18F]FDG activity below the mediastinal blood pool (MBP)

240 10 DZ twin pairs underwent high-resolution [18F]-DOPA PET to assess presynaptic striatal dopamine fu

241 (7 males/8 females) using the oral 14(R,S)-[18F]-fluoro-6-thia-heptadecanoic acid positron emission

242 Sodium 18F-fluoride (18F-NaF) PET/CT imaging is a promising ima

243 More specifically, 18F-AV-1451 binding was significantly increased in patie

244 Striatal [18F]MNI-659 uptake correlated strongly with the severity

245 HD cohort had significantly lower striatal [18F]MNI-659 uptake than did the HV cohort (mean, -48.4%;

246 th aortic stenosis than in control subjects (18F-NaF: 2.87+/-0.82 versus 1.55+/-0.17; 18F-FDG: 1.58+/

247 Rmax/mean), and the maximum blood-subtracted 18F-NaF activity (bsNaFmax).

248 We synthesized 18F-CP18, a caspase-3 substrate and evaluated cardiac 18

249 al community underwent flortaucipir 18 T807 (18F-T807) and carbon 11-labeled Pittsburgh Compound B (1

250 C-PiB) positron emission tomography and tau (18F-AV-1451) positron emission tomography, and episodic

251 nuclear palsy tau deposits for 11C-PBB3 than 18F-AV-1451.

252 These preclinical studies illustrate that 18F-PBR06 is a promising tracer for visualization of TSP

253 ost-mortem autoradiographic data showed that 18F-AV-1451 strongly bound to Alzheimer-related tau path

254 We suggest that 18F-AV-1451 positron emission tomography is a useful bio

255 lear palsy, and a control case to assess the 18F-AV-1451 binding specificity to Alzheimer's and non-A

256 We also examined the 18F-AV-1451 autoradiographic binding in post-mortem tiss

257 assessment of arterial plasma levels of the 18F-DA metabolite 18F-dihydroxyphenylacetic acid (18F-DO

258 The [18F]-AV-1451 SUVR in the hippocampus and AD cortical sig

259 r in vivo evidence that distribution of the [18F]AV-1451 signal as seen on results of PET imaging is

260 iated with the regional distribution of the [18F]AV-1451 signal.

261 ative-associated variability; and (iii) this 18F-AV-1451 positron emission tomography retention patte

262 on emission tomography binding antecedent to 18F-AV-1451 positron emission tomography scans, and to w

263 ange in florbetapir retention, antecedent to 18F-AV-1451 positron emission tomography scans, in the p

264 8F-florbetapir positron emission tomography, 18F-fludeoxyglucose positron emission tomography, struct

265 with the positron emission tomography tracer 18F-AV-1451) associated with well-established Alzheimer'

266 and Rluc bioluminescence reporters plus two 18F-labeled PET reporters FHBG [9-(4-18F-fluoro-3-[hydro

267 eposition was associated with the underlying 18F-flourodeoxyglucose uptake (inflammatory signal), mea

268 Patients underwent [18F]AV-1451 PET imaging to measure tau burden, carbon 11

269 cohorts of 10 healthy volunteers underwent [18F]FMISO or 15O PET.

270 ol study included 10 patients who underwent [18F]FMISO and 15O PET within 1 to 8 days of severe or mo

271 rial and LN inflammation were measured using 18F-fluorodeoxyglucose positron emission tomography.

272 e mean U87MG tumor volume was 35.0 mm3 using 18F-FDG and 34.1 mm3 with 11C-MeAIB, compared with 33.7

273 nding T87 tumor volumes were 122.1 mm3 using 18F-FDG, 118.3 mm3 with 11C-MeAIB, and 125.4 mm3 by hist

274 histology-derived volumes was obtained using 18F-FDG, MAP3D reconstruction, and fixed thresholding of

275 itron emission and computed tomography using 18F-NaF and 18F-FDG radiotracers.

276 Using [18F]-DOPA positron emission tomography (PET), we sought

277 n (hyperinsulinemic-euglycemic clamp) using [18F]fluorodeoxyglucose scanning.

278 Response to treatment was evaluated using [18F] fluorodeoxyglucose positron emission tomography (PE

279 ge-matched controls born at full term using [18F]-DOPA PET and structural MRI.

280 ers with positron emission tomography using [18F]fluorodeoxyglucose.

281 scan-rescan reproducibility of aortic valve 18F-fluoride PET-CT imaging.

282 icant correlation was noted between valvular 18F-FDG uptake and change in calcium score (r=-0.11; P=0

283 ts with PD+OH or PAF had decreased vesicular 18F-DA uptake and accelerated 18F-DA loss, compared with

284 and may show improved agreement with visual [18F]flutemetamol PET assessment when using the Abeta42:A

285 assay showed better concordance with visual [18F]flutemetamol PET status (area under the receiver ope

286 :Abeta40 and Abeta42:tau ratios with visual [18F]flutemetamol PET status.

287 this improved further (r=0.75; P<0.01) when 18F-NaF uptake overlying computed tomography-defined mac

288 This study aimed to determine whether 18F-fludeoxyglucose-positron emission tomography/compute

289 ally high agreement (95%; kappa = 0.89) with 18F-flutemetamol positron emission tomography in the val

290 Determination of skeletal tumor burden with 18F-fluoride PET/CT is feasible and highly reproducible.

291 method to assess skeletal tumor burden with 18F-labeled sodium fluoride PET/CT (18F-fluoride PET/CT)

292 Dynamic PET imaging with 18F-FDG (7.7+/-0.9 MBq) was conducted.

293 id positron emission tomography imaging with 18F-flutemetamol.

294 ship between tau pathology, as measured with 18F-AV-1451-PET imaging, and cognitive deficits in Alzhe

295 ng disease-specific metabolism patterns with 18F-FDG PET compared with that of clinical diagnosis.

296 metabolism in Parkinson's disease (PD) with 18F-fluorodeoxyglucose (FDG) positron emission tomograph

297 Recent studies using PET with 18F-fluorodeoxyglucose (18FDG) have shown the presence o

298 Positron emission tomography with 18F-florbetapir and fludeoxyglucose was used to quantify

299 mental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study is a multicenter stud

300 PET with [18F]fluoro-2-deoxy-D-glucose can be used to image cellul

301 fest HD mutation carriers were scanned with [18F]-fluorodeoxyglucose PET to measure cerebral metaboli